Barzolvolimab is under clinical development by Celldex Therapeutics and currently in Phase II for Prurigo. According to GlobalData, Phase II drugs for Prurigo have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Barzolvolimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Barzolvolimab overview
Barzolvolimab (CDX-0159) is under development for the treatment of chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), eosinophilic esophagitis (EoE), prurigo nodularis and atopic dermatitis. The drug candidate is a second generation version of CDX-0158 (fragment crystallizable (Fc) portion of CDX-0158 antibody). It acts by targeting tyrosine protein kinase Kit. It is administered through intravenous and subcutaneous route in the form of suspension or solution.
The drug candidate was also under development for the treatment of unspecified cancer.
Celldex Therapeutics overview
Celldex Therapeutics (Celldex) is a biopharmaceutical company. It focuses on advancing mast cell biology and developing therapeutic antibodies to treat severe inflammatory, allergic, autoimmune, and other debilitating diseases. The company’s primary candidate, barzolvolimab (CDX-0159), targets the KIT receptor and is under evaluation for multiple mast cell-related conditions. An ongoing Phase 2 study in chronic spontaneous urticaria has achieved its primary efficacy endpoint, with additional Phase 2 studies in chronic inducible urticaria, prurigo nodularis, and eosinophilic esophagitis underway. The company is also expanding its pipeline with a bispecific antibody, CDX-585, which combines PD-1 and anti-ILT4 blockade to enhance anti-tumor immunity, currently in a Phase 1 study for advanced solid tumors. Celldex is headquartered in Hampton, New Jersey, the US.
For a complete picture of Barzolvolimab’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
